Binley, J. M., S. Ngo-Abdalla, P. Moore, M. Bobardt, U. Chatterji, P. Gallay, D. R. Burton, I. A. Wilson, J. H. Elder and A. de Parseval (2006). "Inhibition of HIV Env binding to cellular receptors by monoclonal antibody 2G12 as probed by Fc-tagged gp120." Retrovirology 3: 39.

 

 

Cebere, I., L. Dorrell, H. McShane, A. Simmons, S. McCormack, C. Schmidt, C. Smith, M. Brooks, J. E. Roberts, S. C. Darwin, P. E. Fast, C. Conlon, S. Rowland-Jones, A. J. McMichael and T. Hanke (2006). "Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers." Vaccine 24(4): 417-425.

 

 

Dean, H. J. (2006). "Alternative routes of influenza vaccine delivery." Expert Opin Drug Deliv 3(5): 557-561.

 

 

Excler, J. L. (2006). "AIDS vaccine efficacy trials: expand capacity and prioritize. 'Throughout Africa, Asia and Latin America state-of-the-art clinics and laboratories...exist where, 4 years ago, there were none'." Expert Rev Vaccines 5(2): 167-170.

 

 

Fast, P. E. (2006). "Recent trends in clinical trials of vaccines to prevent HIV/AIDS." Curr Opin HIV AIDS 1(4): 267-271.

 

 

Goonetilleke, N., S. Moore, L. Dally, N. Winstone, I. Cebere, A. Mahmoud, S. Pinheiro, G. Gillespie, D. Brown, V. Loach, J. Roberts, A. Guimaraes-Walker, P. Hayes, K. Loughran, C. Smith, J. De Bont, C. Verlinde, D. Vooijs, C. Schmidt, M. Boaz, J. Gilmour, P. Fast, L. Dorrell, T. Hanke and A. J. McMichael (2006). "Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes." J Virol 80(10): 4717-4728.

 

 

Gupta, K. and P. J. Klasse (2006). "How do viral and host factors modulate the sexual transmission of HIV? Can transmission be blocked?" PLoS Med 3(2): e79.

 

 

Hecht, R., A. Alban, K. Taylor, S. Post, N. B. Andersen and R. Schwarz (2006). "Putting it together: AIDS and the millennium development goals." PLoS Med 3(11): e455.

 

 

Hecht, R. and C. Suraratdecha (2006). "Estimating the demand for a preventive HIV vaccine: why we need to do better. Reliable estimates would help in achieving several policy and advocacy objectives." PLoS Med 3(10): e398.

 

 

Khurana, S., J. Needham, S. Park, B. Mathieson, M. P. Busch, G. Nemo, P. Nyambi, S. Zolla-Pazner, S. Laal, J. Mulenga, E. Chomba, E. Hunter, S. Allen, J. McIntyre, I. Hewlett, S. Lee, S. Tang, E. Cowan, C. Beyrer, M. Altfeld, X. G. Yu, A. Tounkara, O. Koita, A. Kamali, N. Nguyen, B. S. Graham, D. Todd, P. Mugenyi, O. Anzala, E. Sanders, N. Ketter, P. Fast and H. Golding (2006). "Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies: utility for detection of diverse HIV-1 subtypes." J Acquir Immune Defic Syndr 43(3): 304-312.

 

 

Koff, W. C., P. R. Johnson, D. I. Watkins, D. R. Burton, J. D. Lifson, K. J. Hasenkrug, A. B. McDermott, A. Schultz, T. J. Zamb, R. Boyle and R. C. Desrosiers (2006). "HIV vaccine design: insights from live attenuated SIV vaccines." Nat Immunol 7(1): 19-23.

 

 

Luzuriaga, K., M. L. Newell, F. Dabis, J. L. Excler and J. L. Sullivan (2006). "Vaccines to prevent transmission of HIV-1 via breastmilk: scientific and logistical priorities." Lancet 368(9534): 511-521.

 

 

Pitisuttithum, P., P. Gilbert, M. Gurwith, W. Heyward, M. Martin, G. van, D. Hu, J. Tappero and K. Choopanya (2006). "Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand." J Infect Dis 194: 1661 - 1671.

 

 

Price, M. A., S. R. Stewart, W. C. Miller, F. Behets, W. H. Dow, F. E. Martinson, D. Chilongozi and M. S. Cohen (2006). "The cost-effectiveness of treating male trichomoniasis to avert HIV transmission in men seeking sexually transmitted disease care in Malawi." J Acquir Immune Defic Syndr 43(2): 202-209.

 

 

Wang, S., R. Pal, J. R. Mascola, T. H. Chou, I. Mboudjeka, S. Shen, Q. Liu, S. Whitney, T. Keen, B. C. Nair, V. S. Kalyanaraman, P. Markham and S. Lu (2006). "Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E." Virology 350(1): 34-47.